By Jake B. Guinto, PhD, Manager, Oncology Drugs & Biologics
On Friday, September 9th and Saturday, September 10th, the National Comprehensive Cancer Network® (NCCN®) hosted the NCCN 6th Annual Congress: Hematologic Malignancies™ in New York. The two-day session was attended by nearly 800 people and included expert clinicians, nurses, pharmacists, and other health care professionals interested in keeping abreast of NCCN recommendations, clinical studies, and future developments in the care of hematological malignancies. The esteemed faculty included experts from the following NCCN Member Institutions: Memorial Sloan-Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Dana-Farber/Brigham and Woman's Cancer Center, Roswell Park Cancer Institute, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, and Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.
Speakers presented NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) and focused on a number of topics. Andrew D. Zelenetz, MD, PhD of Memorial Sloan-Kettering Cancer Center and chair of the NCCN Guidelines Panel for Non-Hodgkin's Lymphomas, discussed the role of maintenance therapy in follicular lymphoma. Other sessions focused on chronic lymphocytic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, and multiple myeloma. Speakers discussed current standard-of-care therapies for these cancers, ongoing clinical trials, future promising therapies, and other issues relating to these cancers. For a number of participants, there was also a satellite lunch symposium moderated by Myron S. Czuczman, MD of Roswell Park Cancer Institute, who spoke on the latest advancements in follicular lymphoma.
Additional topics included a session on the evolving etiology and management of infections in patients with a hematologic malignancy, a session on hematopoietic stem cell transplantation, and a session on post-transplant lymphoproliferative disorders. The meeting ended with a supportive care module, which included presentations on the management of cancer-related anemia and prevention and management of venous thromboembolic disease.
This range of timely and important presentations in conjunction with the technologies, products, and programs showcased by exhibitors provided attendees with a rich and educational experience. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances, and the NCCN 6th Annual Congress: Hematologic Malignancies™ once again proved an effective and innovative forum for doing so.